BERG Presents Initial Clinical Data And Identification Of Response Biomarkers In A Phase 2 Pancreatic Cancer Trial Guided By Using The Interrogative Biology® Platform At ASCO-GI Meeting

BERG Presents Initial Clinical Data And Identification Of Response Biomarkers In A Phase 2 Pancreatic Cancer Trial Guided By Using The Interrogative Biology® Platform At ASCO-GI Meeting CLICK HERE to Read This Article At The Original Source

FRAMINGHAM, Mass., Jan. 24, 2020 /PRNewswire/ — BERG, a biopharmaceutical company that merges biology with technology to map and identify drivers of diseases, today announced the presentation of initial results from a Phase 2 clinical trial at the Gastrointestinal Cancer Symposium…

Author: HEDGE

Hedge Accordingly was founded ahead of the global financial crisis in January of 2008, with the goal of providing our readers our unique take on The Latest News on Wall Street, Stocks, #Politics and Business news. Hedge Accordingly produces both original, and aggregated #Wallst news content from top publishers around the world. We curate aggregated content covering the latest news on politics, stocks, wall street, and the tech industry. We also provide free stock charting, quotes and a bitcoin, forex and currency exchange. Learn More About HEDGEaccordingly.com